PARP inhibitor combined with platinum activates the cGAS-STING pathway to enhance anti-PD-L1 immunotherapy in lung adenocarcinoma

Key Points

• PARP inhibitor and platinum treatment significantly enhances the anti-PD-L1 response.
• The cGAS-STING pathway activation shows a potential connection between therapies.
• Combination therapy was tested on lung adenocarcinoma models, showcasing promising results.
• Findings imply the necessity for further validation in human trials for enhanced immunotherapy.